A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

Phase 3 Active not recruiting 378 enrolled Medigen Vaccine Biologics Corp.

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the immunogenicity and safety of EV71 vaccine (Envacgen®) in Children Aged 6 to \<10 Years compared to Children Aged 2 to \<6 Years.

Timeline

Start: 2025-06-25
Primary completion: 2026-07-31
Completion: 2026-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Envacgen®	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.